Highlights
- CG Oncology shares closed at US$84.78 on 16 November 2026, up 13.95%, with 9.88 million shares traded.
- Phase 3 PIVOT-006 met its primary endpoint, showing a 68% reduction in recurrence risk compared with surveillance alone.
- The hazard ratio was 0.32, with a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001.
- A Biologics License Application for high-risk BCG-unresponsive bladder cancer is expected to be completed in the fourth quarter of 2026.
A late-stage bladder cancer trial delivered a clear readout and a strong market response. CG Oncology, Inc. (NASDAQ:CGON) closed at US$84.78 on 16 November 2026, up 13.95%, with 9.88 million shares traded and Market Capitalisation near US$7.6 billion. The Dallas-based company announced that its Phase 3 PIVOT-006 study had met its primary endpoint.
PIVOT-006 Results
The trial enrolled 367 patients at about 90 sites across the United States and Canada. It evaluated cretostimogene grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer, compared with surveillance.
The study showed a 68% reduction in the risk of recurrence, with a hazard ratio of 0.32, a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001. The population that could be addressed is about 50,000 patients.
Relative Volume of 6.25 means turnover was more than six times the recent average, a level consistent with major clinical news.
Regulatory Path and Upcoming Data
The company expects to complete a Biologics License Application for high-risk BCG-unresponsive non-muscle invasive bladder cancer in the fourth quarter of 2026. A Benzinga report also mentions two BLA filings planned for 2027.
Additional data are expected in December 2026, including 12-month results from BOND-003 Cohort P and CORE-008 Cohort CX.
PIVOT-006 studied therapy given after tumour removal to lower the chance of recurrence, a setting in which patients are otherwise monitored under surveillance.
Financial Position
CG Oncology reported a third-quarter net loss of US$56.9 million on 6 November 2026, with Earnings Per Share ahead of analyst estimates. At the end of fiscal 2025, the company had about US$903 million in cash, which management said would fund operations into the first half of 2029.
Large cash reserves give the company flexibility to prepare for regulatory filings and potential commercial activity.
Strong data in a large patient population can broaden the commercial opportunity, although approval decisions rest with regulators. Investors typically look at the strength of the efficacy signal alongside safety, durability of response and the size of the treated population.
Sector Context and Risks
Non-muscle invasive bladder cancer is a large field where treatments often involve repeated procedures and high recurrence rates. Oncolytic immunotherapies like cretostimogene seek to kill tumour cells and trigger an immune response.
Regulatory review outcomes, safety profile, competition and commercial execution remain uncertain. Investors may follow the filing timeline and the December data updates.
Oncolytic virus therapies are a niche class with few approved products, so the regulatory path and Manufacturing consistency are watched closely. Competition in bladder cancer includes other immunotherapies and gene therapies, which may shape how new Options are positioned.
_11_17_2026_06_50_14_402066.jpg)





Please wait processing your request...